Form Type: 4

SEC EDGAR Link
Accession Number:0001562180-23-003922
Date:2023-05-01
Issuer: EDGEWISE THERAPEUTICS, INC. (EWTX)
Original Submission Date:

Reporting Person:

MOORE JOHN R
C/O EDGEWISE THERAPEUTICS, INC.
3145 COLORADO AVE BOULDER, CO 80303

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2023-05-01 M 5,208 a $0.00 8,462 direct
COMMON STOCK 2023-05-02 S 1,897 d $8.90 6,565 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
RESTRICTED STOCK UNITS 0.0 2023-05-01 deemed execution date M 5,208 (d) 2032-05-01 common stock 5,208 $0.00 10,417 direct
Footnotes
IDfootnote
f1 includes 254 shares purchased on november 15, 2022 pursuant to the edgewise therapeutics, inc. 2021 employee stock purchase plan.
f2 represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units (rsus). this sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the reporting person.
f3 the price reported in column 4 is an average price. these shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. the reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
f4 rsus granted to the reporting person which represent a contingent right to receive one share of edgewise therapeutics, inc. common stock upon the vesting of these rsus in three equal annual installments beginning on may 1, 2023.
WhaleWisdom Logo

Elevate your investments